In the ever-evolving world of biotechnology, innovation is the key to advancing drug discovery, therapeutic development and a deeper understanding of biological processes. BioPharmaSpec scientists have always been at the forefront of instrument innovation - notably our Chairman, Prof. Howard R. Morris, conceived the Q-TOF geometry for mass spectrometers in the 1990s - and we continue to drive pioneering innovation for our clients.
One of the most exciting recent advancements in our labs is the addition of the Aurora TX instrument from RedShiftBio. This cutting-edge tool is redefining how researchers analyze secondary structure of biomolecules, particularly proteins, and their complex behaviors. The positive impact this instrument will have on our own clients’ development projects is clear: a multitude of benefits that streamline research, enhance accuracy, and accelerate time-to-market for their drugs.
At the heart of many breakthroughs in biotechnology is the analysis of protein molecules, something that we at BioPharmaSpec know a little about! The Aurora TX offers unparalleled sensitivity in measuring protein secondary structure and stability. This sensitivity is critical for our clients in the biotech industry, as even the smallest changes in protein structure can affect a drug’s efficacy or safety.
Our traditional methods of protein secondary structure analysis, such as circular dichroism (CD) and infrared (IR) spectroscopy, have some limitations, especially when it comes to sensitivity and dynamic range. RedShift BioAnalytic’s Aurora TX surpasses these methods by using Microfluidic Modulation Spectroscopy (MMS), a novel technology that allows for more precise measurements at much lower sample concentrations. This improved sensitivity enables us to detect subtle changes in protein structure and behavior that might be missed by conventional instruments. With greater accuracy, we can produce even more reliable data for our clients, leading to safer, more effective therapies.
We all know that the development of new drugs is a lengthy and expensive process, often taking years and billions of dollars to bring a single therapeutic to market. One of the key bottlenecks in this process is the accurate and efficient structural characterization of the biologics. The Aurora TX is designed to accelerate drug development by providing faster, more comprehensive analysis of biomolecules.
The innovative instrument allows an assessment of secondary structural changes across a thermal ramp (if required) by applying automated temperature stress in a repeatable fashion to monitor any structural changes as a function of temperature and guide decision-making and candidate ranking, saving valuable R&D time and providing invaluable information relating to the stability of the product.
The ability to perform high-throughput analysis with the Aurora TX allows our scientists to quickly screen multiple product formulations and products under different conditions, identifying potential therapeutic candidates more efficiently by understanding how they interact with various formulation matrices. This instrument also significantly reduces the time required to understand the stability and structural integrity of biologics, which are critical factors in determining whether a drug can move forward in the development pipeline.
Many traditional methods for analyzing proteins, such as CD and IR spectroscopy, often require large sample volumes or higher sample concentrations, the production of which can impact the biomolecules being studied. In contrast, the MMS technology used by the Aurora TX allows researchers to analyze proteins in their native state without the need for excessive sample preparation or harsh conditions.
This non-destructive approach is particularly valuable where sample availability can be limited, especially in the early stages of drug development. Using the Aurora TX, BioPharmaSpec scientists can obtain crucial structural and stability data from small amounts of your sample without the risk of damaging or altering the protein. This not only preserves valuable resources but also provides more accurate insights into how a biologic will perform under real-world conditions.
In addition to its sensitivity and non-destructive capabilities, the Aurora TX offers advanced data collection and interpretation features. Its software platform integrates seamlessly with data analysis tools, allowing us to provide our clients with deeper insights into their samples. The instrument provides real-time data on protein behavior, offering detailed information on secondary structure and thermal stability with minimal hands-on time.
Moreover, the Aurora TX generates high-resolution data that can be readily shared across our BioPharmaSpec teams of experts, making collaboration easier and more effective. This feature is particularly useful where cross-functional teams need to analyze and interpret data quickly to make informed decisions, such as in biosimilar comparability studies.
Enhanced data transparency leads to better communication, faster problem-solving and more informed decision-making in the drug development process.
For biotech companies, ensuring compliance with regulatory standards is crucial. Regulatory agencies such as the FDA and EMA require extensive data on the safety, efficacy, and stability of therapeutic proteins. The Aurora TX helps us meet these requirements by providing highly accurate and reproducible data on protein structure and stability.
BioPharmaSpec is excited to announce the addition of RedShift BioAnalytic’s Aurora TX instrument to our range of high-end protein characterization instruments and solutions! The Aurora TX is aligned with our ethos of accelerating drug development for our clients wherever we can, in the most cost-efficient and scientifically sound ways.
Find out how our scientists can help you bring innovative therapies to market quickly and reliably.
